About Admune Therapeutics
Admune Therapeutics is a company based in Danvers (United States) founded in 2013 was acquired by Novartis in October 2015. Admune Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Danvers, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Admune Therapeutics
Detailed funding history for Admune Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Admune Therapeutics
Admune Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
Locked | Locked | Locked |
Investor details for Admune Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Admune Therapeutics
Investment portfolio details for Admune Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Admune Therapeutics
Detailed financials for Admune Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Admune Therapeutics Comparisons
Peer comparison for Admune Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Admune Therapeutics
Admune Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Admune Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Admune Therapeutics
Complete news archive for Admune Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Admune Therapeutics
Admune Therapeutics was founded in 2013.
Admune Therapeutics is headquartered in Danvers, United States. It is registered at Danvers, Massachusetts, United States.
Admune Therapeutics, affiliated with Marine Polymer Technologies is a clinical-stage biotech company that develops cytokine therapy drugs for the treatment of metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others. It has proprietary technologies for the production and use of heterodimeric IL-15Ra (hetIL-15) in cancer immunotherapy. The program is currently in phase 1 clinical trial through the National Cancer Institute at the National Institutes of Health. Admune was acquired by Novartis on Oct 21, 2015 and is currently operating as its subsidiary.
Admune Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Admune Therapeutics has 1 investor. Key investors include Novartis.